Our study found that the expression of FERMT2 and FERMT3 was remarkably correlated with the immune infiltration of six immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells) in LUAD and LUSC, suggesting that FERMT2 and FERMT3 may be potential biomarkers of NSCLC for immune checkpoint blockade therapy. This evidence concerns the gene FERMT3 and non-small cell lung carcinoma.